David Essam News Today

Careers specialist Frontline Recruitment is celebrating after being named Best National Recruitment firm at the UK Recruitment Awards. The awards

Thirty years ago, a British researcher set out to stop the disease – now, the life-changing result of his work could be available on the NHS

Lecanemab is the first drug to remove damage, but there are questions around its impact, side effects and use.

Full results have been published in the new england journal of medicine. the effects of the treatment, called lecanemab, were small, but have prompted huge excitement among researchers. 0ur medical editor, fergus walsh, reports. could you get the broccoli out of the fridge for me, please, love? yeah, 0k. david essam is 78 and has early stage alzheimers. its taken away his independence. hes now totally reliant on me or other people around him. he used to be a joiner, but no longer remembers how t...

A very warm welcome. and we have a packed programme for you today, so lets get started. its being described as a momentous and historic breakthrough. a major trial of an experimental dementia drug has shown — for the first time — that the progression of early stage alzheimers disease can be slowed down. nearly 2000 patients took part in the study, including some here in the uk. full results have been published in the new england journal of medicine. the effects of the treatment were small, b...

Perfect drug, but in a very modest way it— perfect drug, but in a very modest way it can — perfect drug, but in a very modest way it can slow the decline from alzheimers. so even though it is very modest, that is highly significant.— very modest, that is highly siunificant. �* , significant. and they say is an international _ significant. and they say is an international story _ significant. and they say is an international story in - significant. and they say is an international story i...

Is a significant moment in the fight against alzheimers. fergus walsh, bbc news. were joined now by susan kohlhaas, director of research at alzheimers research uk. morning to you. lots of people watching this morning will see this story, see the headline and then, at last, something. haifa story, see the headline and then, at last, something.— last, something. how positive is this? this _ last, something. how positive is this? this is _ last, something. how positive is this? this is an _ last,...

The symptoms of cognitive impairment and also the behavioural- symptoms associated - with alzheimers disease. david and his wife cheryl cant be sure if the drug is making a difference, but theyre delighted to have taken part in the trial. when we first began this two and a half years ago, we didnt necessarily think it would help us, but we felt we were doing something and could help future generations. its just a horrible, nasty thing because if you... if you... if somebody can slow it down, and...

In memory and understanding. david is one of nearly 2,000 patients who took part in a major trial of a new drug — lecanemab. as normal, if you just - lift your arm up there for me. it involved having an infusion every two weeks. lecanemab didnt stop alzheimers... illjust get you started here. ..but over 18 months, its slowed its progression by about a quarter. this is so exciting because now were getting results, - the first results that - are indicating that the drug is successfully treating ...

No, its not. so, some of those who took— no, its not. so, some of those who took part— no, its not. so, some of those who took part suffered brain swelling and also — took part suffered brain swelling and also bleeds in the brain. so patients— and also bleeds in the brain. so patients need to be carefully monitored. but i can tell you that the patients i might like david, and another— the patients i might like david, and another couple, who didnt know whether— another couple, who did...